Bevacizumab May Overcome Clinical Tumor Drug Resistance to IrinotecanBased Chemotherapy in Patients with Metastatic Colorectal Cancer:Case Report

Abstract

Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response. Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third line FOLFIRI/bevacizumab. Conclusion: Retreatment with bevacizumab in combination with a failing chemotherapy regimen is a possible treatment option after exhaustion of all standard treatments. This approach seems to be effective in overcoming clinical tumor drug resistance to irinotecan based chemotherapy